Study reveals how a new IgE antibody therapy reactivates immune cells, offering a promising approach to fighting ovarian ...

Research has shed light on how a new type of antibody treatment reactivates patients’ immune cells to fight ovarian cancer.

A biotech company developing precision therapeutics that selectively eliminate pathogenic antibodies driving autoimmune and ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

Hospitals are witnessing a surge in allergy cases, with patients experiencing sneezing, runny noses, and itchy eyes. Doctors ...

Research has shed light on how a new type of antibody treatment reactivates patients’ immune cells to fight ovarian cancer.

In a recent Fox News interview, Kennedy said "there's a lot of studies out there that show that if you actually do get the ...

The financial terms of the deal were not disclosed, but TigaTx will become a wholly owned subsidiary of Epsilogen as part of ...

The latest biotech to roll out of Third Rock Ventures is working on Fc-based therapeutics it hopes could offer new treatment ...

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.